Seres Therapeutics Faces Nasdaq Challenge Amid Trial Success
Company Announcements

Seres Therapeutics Faces Nasdaq Challenge Amid Trial Success

The latest announcement is out from Seres Therapeutics ( (MCRB) ).

Seres Therapeutics faces a Nasdaq compliance challenge as its stock fell below the $1 bid price requirement, prompting a 180-day period to rectify the situation or face potential delisting. Meanwhile, the company reported promising results from its SER-155 trial, showing a significant reduction in bloodstream infections among patients, which could lead to breakthrough therapy designation. Financially, Seres completed the sale of its VOWST business, bolstering funding for operations into late 2025, while actively seeking a strategic partnership to expand SER-155’s market reach.

Learn more about MCRB stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlySeres Therapeutics reports Q3 EPS 58c, consensus (24c)
TheFlySeres Therapeutics expects cash to fund operations into Q4 of 2025
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App